- Home
- PTA vs MRVI Comparison
PTA vs MRVI Comparison
Compare PTA & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PTA | MRVI |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 942.4M | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PTA | MRVI |
|---|---|---|
| Price | $17.25 | $7.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 303.0K | ★ 2.4M |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | ★ 8.31% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | N/A | $14.01 |
| Revenue Next Year | N/A | $6.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.66 | $2.55 |
| 52 Week High | $19.98 | $9.42 |
Technical Indicators
Market Signals| Indicator | PTA | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 52.45 | 47.68 |
| Support Level | $16.66 | $6.41 |
| Resistance Level | $19.53 | $7.60 |
| Average True Range (ATR) | 0.19 | 0.52 |
| MACD | 0.09 | 0.05 |
| Stochastic Oscillator | 92.19 | 42.26 |
Price Performance
Historical ComparisonAbout PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its main investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.